Buying cures versus renting health: Financing health care with consumer loans

Science Translational Medicine

Volumn 8, Issue 327, 2016, Pages

  Montazerhodjat, Vahid ^a,b   Weinstock, David M ^c,d   Lo, Andrew W ^a,b,e,f  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b Department of Electrical Engineering and Computer Science   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^e MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^f AlphaSimplex Group LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; RIBAVIRIN;

COMPUTER SIMULATION; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG AFFORDABILITY; DRUG COST; FINANCIAL MANAGEMENT; FUNDING; GOVERNMENT REGULATION; HEALTH CARE ACCESS; HEALTH CARE DISPARITY; HEALTH CARE LOAN; HEALTH CARE POLICY; HEALTH ECONOMICS; HEALTH INSURANCE; HEPATITIS C; HUMAN; MEDICAL CARE; MONTE CARLO METHOD; PATIENT PARTICIPATION; PRIORITY JOURNAL; REIMBURSEMENT; RESOURCE ALLOCATION; REVIEW; RISK REDUCTION; SECURITIZATION; SENSITIVITY ANALYSIS; SURVIVAL RATE; TRANSFORMATIVE THERAPY; ECONOMICS; HEALTH CARE DELIVERY; MOTIVATION;

DELIVERY OF HEALTH CARE; FINANCIAL MANAGEMENT; HUMANS; INSURANCE, HEALTH; MOTIVATION;

EID: 84959432463     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aad6913     Document Type: Review

References (31)

1. E. Lawitz, A.Mangia, D. Wyles,M. Rodriguez-Torres, T. Hassanein, S. C. Gordon, M. Schultz, M. N. Davis, Z. Kayali, K. R. Reddy, I. M. Jacobson, K. V. Kowdley, L. Nyberg, G. M. Subramanian, R. H. Hyland, S. Arterburn, D. Jiang, J. McNally, D. Brainard, W. T. Symonds, J. G. McHutchison, A. M. Sheikh, Z. Younossi, E. J. Gane, Sofosbuvir for previously untreated chronic hepatitis C infection. N. Engl. J. Med. 368, 1878-1887 (2013).
2. M. M. Denniston, R. B. Jiles, J. Drobeniuc, R. M. Klevens, J. W. Ward, G. M. McQuillan, S. D. Holmberg, Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann. Intern. Med. 160, 293-300 (2014).
3. J. P. Messina, I. Humphreys, A. Flaxman, A. Brown, G. S. Cooke, O. G. Pybus, E. Barnes, Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 61, 77-87 (2015).
4. T. A. Brennan, J. M. Wilson, The special case of gene therapy pricing. Nat. Biotechnol. 32, 874-876 (2014).
5. T. Philipson, A. Von Eschenbach, Medical breakthroughs and credit markets. Forbes (9 July 2014). www.forbes.com/sites/tomasphilipson/2014/07/09/medical-breakthroughs-andcredit-markets.
6. S. Mattke, E. Hoch, Borrowing for the cure: Debt financing of breakthrough treatments. (RAND Corporation, Santa Monica, CA, 2015). www.rand.org/pubs/perspectives/PE141.
7. J.-M. Fernandez, R. M. Stein, A. W. Lo, Commercializing biomedical research through securitization techniques. Nat. Biotechnol. 30, 964-975 (2012).
8. D. U. Himmelstein, D. Thorne, E. Warren, S. Woolhandler, Medical bankruptcy in the United States, 2007: Results of a national study. Am. J. Med. 122, 741-746 (2009).
9. S.Mailankody, V. Prasad, Five years of cancer drug approvals: Innovation, efficacy, and costs. JAMA Oncol. 1, 539-540 (2015).
10. M. Sanger-Katz, Prescription drug costs are rising as a campaign issue. New York Times (21 September 2015). www.nytimes.com/2015/09/22/upshot/prescription-drugcosts-are-rising-as-a-campaign-issue.html?rref=upshot.
11. D. M. Cutler, Payment reform is about to become a reality. JAMA 313, 1606-1607 (2015).
12. K. Yamasaki, M. Tomohiro, Y. Nagao, M. Sata, T. Shimoda, K. Hirase, S. Shirahama, Effects and outcomes of interferon treatment in Japanese hepatitis C patients. BMC Gastroenterol. 12, 139 (2012).
13. B. Simmons, J. Saleem, K. Heath, G. S. Cooke, A. Hill, Longterm treatment outcomes of patients infected with hepatitis C virus: A systematic review and meta-analysis of the survival benefit of achieving a sustained virological response. Clin. Infect. Dis. 61, 730-740 (2015).
14. J. Smith-Palmer, K. Cerri, W. Valentine, Achieving sustained virologic response in hepatitis C: A systematic review of the clinical, economic and quality of life benefits. BMC Infect. Dis. 15, 19 (2015).
15. M. H. Lee, H. I. Yang, S. N. Lu, C. L. Jen, S. L. You, L. Y. Wang, C. H. Wang, W. J. Chen, C. J. Chen, R.E.V.E.A.L.-HCV Study Group, Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: A communitybased long-term prospective study. J. Infect. Dis. 206, 469-477 (2012).
16. A. J. Van Der Meer, B. E. Hansen, J. J. Feld, H. Wedemeyer, J.-F. Dufour, F. Lammert, A. Duarte-Rojo, M. P.Manns, S. Zeuzem, W. P. Hofmann, R. J. De Knegt, B. J. Veldt, H. L. A. Janssen, Comparison of the overall survival between patients with HCV-induced advanced hepatic fibrosis and the general population (American Association for the Study of Liver Disease, Washington, D.C., 2013). www.natap.org/2013/AASLD/AASLD-125.htm.
17. S. L. Colby, J. M. Ortman, The baby boom cohort in the United States: 2012 to 2060 (Current Population Reports, P25-1141, U.S. Census Bureau, Washington, D.C., 2014). www.census.gov/prod/2014pubs/p25-1141.pdf.
18. A. J. Van Der Meer, B. J. Veldt, J. J. Feld, H. Wedemeyer, J.-F. Dufour, F. Lammert, A. Duarte-Rojo, E. J. Heathcote, M. P.Manns, L. Kuske, S. Zeuzem, W. P. Hofmann, R. J. De Knegt, B. E. Hansen, H. L. A. Janssen, Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 308, 2584-2593 (2012).
19. I. Donnelly, Thousands of cancer patients to be denied treatment. Telegraph (4 September 2015). www.telegraph.co.uk/news/health/11844314/Thousands-of-cancer-patients-tobe-denied-treatment.html.
20. National Association of Medicaid Directors' Letter to the Congress (Washington, D.C., 28 October 2014). www. medicaiddirectors.org/wp-content/uploads/2015/08/namd-sovaldi-letter-to-congress-10-28-14.pdf.
21. S. A. Ross, R. Westerfield, J. D. Bradford, Fundamentals of Corporate Finance (McGraw-Hill Irwin, New York, 2012).
22. R. A. Brealey, S. C. Myers, A. J. Marcus, Fundamentals of Corporate Finance (McGraw-Hill Irwin, New York, 2012).
23. H. M. Markowitz, Portfolio Selection: Efficient Diversification of Investments, 2nd ed. (Wiley, Hoboken, NJ, 1991).
24. B. P. Lancaster, G. M. Schultz, F. J. Fabozzi, Structured Products and Related Credit Derivatives: A Comprehensive Guide for Investors (Wiley, Hoboken, NJ, 2008), vol. 151.
25. R. L. Kosowski, S. Neftci, Principles of Financial Engineering, 3rd ed. (Academic Press, Cambridge, 2014).
26. J. Bricker, L. J. Dettling, A. Henriques, J. W. Hsu, K. B. Moore, J. Sabelhaus, J. Thompson, R. A.Windle, Changes in U.S. family finances from 2010 to 2013: Evidence from the Survey of Consumer Finances. Federal Reserve Bulletin 100, 1-41 (2014).
27. A. C. Moorman, S. C. Gordon, L. B. Rupp, P. R. Spradling, E. H. Teshale, M. Lu,D. R. Nerenz, C. C.Nakasato, J. A. Boscarino, E. M. Henkle, N. J. Oja-Tebbe, J.Xing, J. W.Ward, S. D. Holmberg, Chronic Hepatitis Cohort Study Investigators, Baseline characteristics and mortality among people in care for chronic viral hepatitis: The chronic hepatitis cohort study. Clin. Infect. Dis. 56, 40-50 (2013).
28. National Student Aid Profile: Overview of 2012 Federal Programs (NASFAA Report, Washington, D.C., 2012).
29. R. Fry, A record one-in-five households now owe student loan debt (Pew Social&Demographic Trends,Washington, D.C., 2012).
30. I. W. Burr, Cumulative frequency functions. Ann. Math. Stat. 13, 215-232 (1942).
31. R. N. Rodriguez, A guide to the Burr type XII distributions. Biometrika 64, 129-134 (1977).